Podcasts about lunenfeld tanenbaum research institute

Guest: Daniel Drucker, a clinician-scientist at the Lunenfeld-Tanenbaum Research Institute at Toronto's Mount Sinai Hospital

A controversial fishing method may release CO2 from the sea floor Bottom trawling is a widely-used fishing method that involves dragging weighted nets that scrape along the seafloor. It's sometimes been criticized for damaging marine ecosystems. Now a new study in Frontiers in Marine Science suggests that it also can release significant amounts of carbon trapped in seafloor sediments into the atmosphere. Trisha Atwood, an associate professor at Utah State University and a marine researcher with National Geographic's Pristine Sea Program worked with scientists at NASA and The Global Fishing Watch for this study. Travel tales a mammoth tusk can tell Researchers have been analyzing the tusk of a woolly mammoth that died in Alaska 14,000 years ago. Using modern chemical analysis, they've been able to track the pachyderm's travels through its life, and the trail it took to its final demise, likely at the hands of human hunters. Dr. Matthew Wooller at the University of Alaska Fairbanks worked with the Healy Lake Village Council, the University of Ottawa and Hendrik Poinar's laboratory at McMaster University on this study published in Science Advances. Common sense is not that common, but is quite widely distributed Sociologists at the University of Pennsylvania have helped answer the age-old question, do most of us have common sense? Researchers including Mark Whiting explored this by asking 2000 people if they agreed with thousands of terms that had been deemed as “common sense.” In a paper published in PNAs, the team found that the larger the group, the less likely there was commonly shared knowledge, and no one age, educational or political group stood out as having more common sense than others. Male birds who practice their songs do better with females A new study suggests that male songbirds who attract mates with their songs need to practice their tunes or their attractiveness suffers. The researchers found a way to harmlessly discourage the birds from singing, and found that without practice females snubbed their efforts. Iris Adam, a biologist at Southern Denmark University, was part of the team, whose research was published in Nature Communications. Better living through pharmacology — Can drugs duplicate a healthy lifestyle? The key to good health used to be simple: eat less and exercise. But popular new weight loss drugs could soon be joined on the shelf with a new class of pharmaceuticals that duplicate the effects of a trip to the gym. We explore just how these new pharmaceuticals work and just how much they can replace a healthy lifestyle. First developed to treat type 2 diabetes, now widely popular as weight loss drugs, GLP-1 agonist drugs like Ozempic may in fact have benefits beyond helping with obesity and cardiovascular disease. Dr. Daniel Drucker, a senior research scientist at Lunenfeld-Tanenbaum Research Institute and the University of Toronto, early evidence suggests they may also work to treat kidney disease, addiction related disorders, metabolic liver disease, peripheral vascular disease, Parkinson's and Alzheimer's. To counter our modern sedentary lifestyles, scientists are also looking for the equivalent of an exercise pill. Ronald Evans, a professor at the Salk Institute, has been working on drugs that control genetic “master switches” that can turn on the same network of genes — and confer many of the same benefits — as a brisk walk or a jog would do.

Although AI has long been associated with science fiction, in recent years, it has become a groundbreaking reality with the potential to transform health care. In this episode, we're going to dive deep into how AI is reshaping the radiology landscape, its short- and long-term impact on the field, how we, as radiologists, need to adapt and what skills we need to add to our toolbox, and most importantly - do we have job security? All about this and more in this episode of Radiologists with our guest, Dr. Masoom Haider, a professor in the department of medical imaging at the University of Toronto, a clinician scientist at the Lunenfeld-Tanenbaum Research Institute and the Ontario Institute of Cancer Research, the Director of Sinai Health Research MRI and the Head of Radiomics and Machine Learning Lab at Sinai Health System in Toronto.Produced by Inna LevchukThanks for listening! Learn more about us at universitymedicalimagingtoronto.ca and follow us on social media @imagingtoronto.

Some scientists believe the key to living longer and aging better lies in a phenomenon called cell senescence, also known as “zombie cells.” We discuss that research with Daniel Durocher, a senior investigator at the Lunenfeld-Tanenbaum Research Institute at Sinai Health in Toronto.

Sustainable Development Goal 16: Peace, Justice, and Strong Institutions focuses on promoting peaceful and inclusive societies for sustainable development, providing access to justice for all and building effective, accountable, and inclusive institutions at all levels.Dr. Ross Upshur is currently the Dalla Lana Chair in Clinical Public Health and Head of the Division of Clinical Public Health at the Dalla Lana School of Public Health, Scientific Director, Bridgepoint Collaboratory for Research and Innovation and Associate Director of the Lunenfeld Tanenbaum Research Institute, Sinai Health. At the University of Toronto, he is a Professor in the Dalla Lana School of Public Health and the Department of Family and Community Medicine, affiliate member of the Institute for the History and Philosophy of Science and Technology, Member of the Centre for Environment and Adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences. He is a Staff Physician at Bridgepoint Active Healthcare, Sinai Health. In 2015, he was named one of the Top 20 Pioneers in Family Medicine Research in Canada by the College of Family Physicians of Canada and was a Tier 2 Canada Research Chair from 2005-2015. He is an elected Fellow of the Hastings Center and the Canadian Academy of Health Sciences. During COVID-19 he has served as the co-Chair of the WHO Ethics and COVID-19 Working group and is a member of the WHO ACTA Ethics and Governance Working Group.Rushay Naik is an MSc student in Health Policy & Global Health at the University of Toronto. His research centres on health service delivery in conflict-affected states, and has conducted fieldwork for research initiatives in Greece, Mongolia, and Switzerland. Rushay has held research fellowships at UofT's School of Cities, at the Center for the Study of the Presidency & the Congress in Washington, D.C., and at the University of Oxford's COVID-19 Government Response Tracker. Rushay previously worked for Health Canada's Climate Change and Innovation Bureau, and is now an incoming intern to the Health Division at the OECD in Paris. CREDITS: This podcast is co-hosted by Dr. Erica Di Ruggiero, Director of the Centre for Global Health, and Ophelia Michaelides, Manager of the Centre for Global Health, at the DLSPH, U of T, and produced by Elizabeth Loftus. Audio editing is by Sylvia Lorico. Music is produced by Julien Fortier and Patrick May. It is made with the support of the School of Cities at U of T. 

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers interpersonal psychotherapy (IPT) with Dr. Paula Ravitz, an Associate Professor of Psychiatry at the University of Toronto and Senior Clinician-Scientist at the Lunenfeld-Tanenbaum Research Institute of Mt Sinai Hospital. Dr. Ravitz held the Morgan Firestone Psychotherapy Chair at the Mount Sinai Hospital from 2011 to 2021 and is a past president of the International Society of Interpersonal Psychotherapy. The learning objectives for this episode are as follows:   By the end of this episode, you should be able to… Define interpersonal psychotherapy Describe the core principles and phases of IPT Become familiarized with some psychological theories underpinning IPT List some patient selection considerations for IPT Describe the efficacy and evidence base for IPT  Understand how IPT is practically carried  out  Briefly compare and contrast IPT to other common psychotherapies   Guest: Dr. Paula Ravitz (paula.ravitz@sinaihealthsystem.ca)   Hosts: Jake Johnston and Sena Gok   Audio editing by: Jake Johnston   Show notes by: Jake Johnston   Interview Content: Introduction - 00:00 Learning objectives - 02:10 Definition/overview of IPT - 02:53 Core principles and phases - 07:20 Psychological theories - 19:30 Patient selection considerations - 24:42 Contraindications - 35:57 Evidence base and history - 38:10 Practical components of IPT - 43:57 Maintenance IPT - 59:52 IPT vs other psychotherapies - 62:56  Closing comments - 71:17 Online IPT course - 74:30   Resources: Summary of IPT written in layman's terms: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/interpersonal-psychotherapy The International Society of Interpersonal Psychotherapy (ISIPT) has a helpful overview of IPT and helpful resources for finding more information and IPT training opportunities: https://interpersonalpsychotherapy.org/ ‘Psychotherapy Essentials to Go' book series mentioned during episode:  https://www.penguinrandomhouse.ca/series/CNL/psychotherapy-essentials-to-go Course for learning IPT mentioned at the end of the episode (email Dr. Ravitz at Paula.Ravitz@sinaihealth.ca to inquire about access): www.learnipt.com     References: Bernecker, S. L., Coyne, A. E., Constantino, M. J., & Ravitz, P. (2017). For whom does interpersonal psychotherapy work? A systematic review. Clinical psychology review, 56, 82–93. https://doi.org/10.1016/j.cpr.2017.07.001 Chaimowitz, G., Weerasekera, P., & Ravitz, P. (2021). Psychotherapy in Psychiatry. The Canadian Journal of Psychiatry, 66(11), 999–1004. https://doi.org/10.1177/07067437211040958 Cuijpers, P., Donker, T., Weissman, M. M., Ravitz, P., & Cristea, I. A. (2016). Interpersonal Psychotherapy for Mental Health Problems: A Comprehensive Meta-Analysis. The American journal of psychiatry, 173(7), 680–687. https://doi.org/10.1176/appi.ajp.2015.15091141  Dennis, C. L., Grigoriadis, S., Zupancic, J., Kiss, A., & Ravitz, P. (2020). Telephone-based nurse-delivered interpersonal psychotherapy for postpartum depression: nationwide randomised controlled trial. The British journal of psychiatry : the journal of mental science, 216(4), 189–196. https://doi.org/10.1192/bjp.2019.275  Elkin, I., Shea, M. T., Watkins, J. T., Imber, S. D., Sotsky, S. M., Collins, J. F., Glass, D. R., Pilkonis, P. A., Leber, W. R., & Docherty, J. P. (1989). National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Archives of general psychiatry, 46(11), 971–983. https://doi.org/10.1001/archpsyc.1989.01810110013002 Klerman, G. L., Dimascio, A., Weissman, M., Prusoff, B., & Paykel, E. S. (1974). Treatment of depression by drugs and psychotherapy. The American journal of psychiatry, 131(2), 186–191. https://doi.org/10.1176/ajp.131.2.186  MacQueen, G. M., Frey, B. N., Ismail, Z., Jaworska, N., Steiner, M., Lieshout, R. J., Kennedy, S. H., Lam, R. W., Milev, R. V., Parikh, S. V., Ravindran, A. V., & CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 61(9), 588–603. https://doi.org/10.1177/0706743716659276 Parikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., Milev, R. V., Ravindran, A. V., Uher, R., & CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 61(9), 524–539. https://doi.org/10.1177/0706743716659418 Ravitz, P., & Watson, P. (2014). Interpersonal Psychotherapy: Healing with a Relational Focus. FOCUS, 12(3), 275-284. https://doi.org/10.1176/appi.focus.12.3.275 Ravitz, P., Watson, P., Lawson, A., Constantino, M. J., Bernecker, S., Park, J., & Swartz, H. A. (2019). Interpersonal Psychotherapy: A Scoping Review and Historical Perspective (1974-2017). Harvard review of psychiatry, 27(3), 165–180. https://doi.org/10.1097/HRP.0000000000000219 Swartz, H. (2021). Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy. UpToDate. Accessed 2021-10-12.   CPA Note: The views expressed in this podcast do not necessarily reflect those of the Canadian Psychiatric Association.   For more PsychEd, follow us on Twitter (@psychedpodcast), Facebook (PsychEd Podcast), and Instagram (@psyched.podcast). You can provide feedback by email at psychedpodcast@gmail.com. For more information, visit our website at psychedpodcast.org.  

Alan Carter talks with Dr. Allison McGeer, Canadian infectious disease specialist in the Sinai Health System, a Professor at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute. The latest data on omicron. How long until we know the severity of omicron? What if we are ALL vaxxed, all have rapid tested, Can we gather more than 10 indoors? See omnystudio.com/listener for privacy information.

Dr. Mandich is a scientist on a mission to help people live their happiest life. I'm a published researcher; two-time TEDx speaker; the founder of The International Happiness Institute of Health Science Research; and you can often find me in the media on shows such as The Social, Marilyn Denis, Breakfast Television, and The Morning Show. Dr. Mandich was the lead speaker for an event that I hosted for Venture Sinai, a charity that raises funds for vital research at the Lunenfeld Tanenbaum Research Institute at Sinai Health System in Toronto, Ontario. The event took place over Zoom during the COVID pandemic in June of 2020. She was such a dynamic and engaging speaker and her talk was well researched and delivered in a way that was easily understood and useful. The feedback that we received from our members and donors was stellar. There were pearls of wisdom imparted that could be used in our everyday lives that I still follow. Dr. Mandich exudes such positive energy and is an absolute pleasure to listen and learn from. I highly recommend hiring her as a speaker for groups of any size. I will be having her speak again at another event that I am organizing. --- Support this podcast: https://anchor.fm/evinweiss/support

In honour of our 100th episode here at Raw Talk Podcast, we are celebrating another anniversary this year: 100 years since the discovery of insulin, a life saving treatment for diabetes that happened here at the University of Toronto. This discovery earned the scientists behind it the 1923 Nobel Prize in Medicine, and was a pivotal moment in Canadian medical science research. In this episode, we sat down with Dr. Daniel Drucker, a senior scientist at the Lunenfeld Tanenbaum Research Institute who gave us a crash course on diabetes, insulin, and the research leading up to the discovery of insulin. Next, we spoke with Jennifer Da Cruz, a diabetes patient, educator and public health nurse at Unison Health and Community Services in Toronto. Finally, we met with Dr. Paraish Misra, a nephrologist, and a PhD candidate in the Nostro lab at the University of Toronto, who told us about some of the exciting new frontiers in stem cell research for diabetes treatment - or possibly even cure. Dr. Daniel Drucker Diabetes Canada Dr. Paraish Misra Open Insulin Foundation Article - The absurdly high cost of insulin, explained Article - Why people with diabetes can't buy generic insulin Review Article - Stem cell-derived insulin-producing cells

今天來唸這一篇： Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v2 研究人員在一項針對梅約醫院醫療體系（Mayo Clinic Health System）5萬多名患者的研究中發現，莫德納疫苗的效力在2021年初有86%，到了7月，即疫情以Delta變異株為主流時，效力降至76%。同一期間，輝瑞/BNT疫苗的效力從76%降至42%。 莫德納抗Delta優於BNT？羅一鈞建議有疫苗就打 https://www.cna.com.tw/news/firstnews/202108100249.aspx 羅一鈞今天下午在指揮中心記者會中說明，上述研究是對比今年上半年流行的Alpha變種病毒成為主流株時期，及6月以後轉換成Delta變種病毒成主流株時期，兩種mRNA疫苗對不同變種病毒的保護力。 該研究發現，BNT疫苗對英國發現的Alpha變種病毒保護力仍有76％，但對源自印度的Delta變種病毒保護力僅剩42％；莫德納疫苗對Alpha變種病毒的保護力為86％，對於Delta變種病毒保護力為76％。雖莫德納疫苗對Delta變種病毒保護效果打折，但仍優於BNT疫苗。 羅一鈞提到，這是第一次有研究顯示不同疫苗對抗變異株效果，COVID-19疫苗對抗變種病毒效果雖會受影響，但仍有一定保護力，不會建議民眾都去打莫德納疫苗或BNT疫苗，呼籲民眾有疫苗就儘速施打。 延伸閱讀 以色列研究：輝瑞&BNT疫苗對Delta防護力僅39% （還沒有詳情發表） https://www.cna.com.tw/news/firstnews/202107243001.aspx BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar https://www.medrxiv.org/content/10.1101/2021.08.11.21261885v1 對抗Delta變異株 莫德納似優於輝瑞 https://www.cna.com.tw/news/firstnews/202108100080.aspx 根據刊載於醫學網站medRxiv的兩篇報告，美國輝瑞和德國BioNTech聯合研發的mRNA（傳訊核醣核酸）疫苗，在抵抗COVID-19的Delta變異株上，效力或許不及莫德納。路透社報導，這兩篇報告尚待同儕審查。medRxiv是收錄尚未發表且未經同儕審查的研究手稿的網路平台。 研究人員在一項針對梅約醫院醫療體系（Mayo Clinic Health System）5萬多名患者的研究中發現，莫德納疫苗的效力在2021年初有86%，到了7月，即疫情以Delta變異株為主流時，效力降至76%。同一期間，輝瑞/BNT疫苗的效力從76%降至42%。 隸屬麻州數據分析公司nference、主導梅約這份研究的桑達拉拉然（Venky Soundararajan）說，儘管兩支疫苗依舊可有效預防因新冠而住院，今年稍早注射輝瑞（Pfizer）/BNT或莫德納疫苗的民眾，可能很快就必須追加一劑莫德納加強劑。 而在另一份研究中，加拿大安大略省老人之家住民接種莫德納疫苗之後所產生的免疫反應，強過輝瑞/BNT疫苗，尤其在對抗讓人憂心的幾種變異株上。主導這項研究的多倫多「魯能費爾德-塔能鮑姆研究所」（Lunenfeld-Tanenbaum Research Institute）研究員金格拉斯（Anne-Claude Gingras）表示，年長者或許需要較高劑量、加強劑和其他預防措施。 路透社尋求輝瑞評論這兩份研究時，輝瑞發言人表示：「我們持續認為…完整接種之後的6到12個月內或許需要追加第3劑加強劑，以維持最高保護力。」 Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1 混打疫苗可行嗎？AZ混打輝瑞/BNT AZ混打莫德納等等 https://linshibi.com/?p=39613 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

台北嘉玲！今日本土僅3例。 雖然不以清零為目標，但看到嘉玲回娘家還是很開心呀。 回頭想想，從五月中到現在能到接近清零的狀態，台灣沒有停止上班，沒有嚴峻的封城。 疫苗一劑覆蓋率衝到近4成了，醫護人員和易重症的老人家覆蓋率更高。 檢驗量能從一萬多增加到一日12萬，抓出了很多無症狀感染者，試著斷去傳染鏈。 這下半場的第一次段考，雖然一開始表現立足未穩，但我們撐過來了，而且表現還可以吧？ 直到目前，我在台北街頭看到口罩覆蓋率是100%。你們呢？ Delta一度進到屏東，但在廣泛匡列下，我們硬是把他擋下來了。 很感謝全台灣民眾的努力，Alpha/Delta都不是好惹的，但我們做到了！ 幫大家打個預防針，接下來我估計還是會有零星案例，甚至一些小小的群聚都可能發生。但只要能夠及時框列隔離，把感染控制在一定範圍，我相信台灣可以走出一條防疫和經濟兼顧的路來的。 第二次段考的考題很明顯，老師已經和你說要考Delta了。 我們對Delta的超前佈署夠了嗎？有什麼還不足之處呢？ 現在還在二級警戒，心態可以輕鬆，但行為不能放鬆。 我們要好好觀察國外學長姊應考的狀況，穩健的走下去。 8/10本土確診增3例創疫情警戒新低 個案皆來自新北 https://www.cna.com.tw/news/firstnews/202108105003.aspx 陳時中說，個案分布均在新北市；其中2例為已知感染源、1例關聯不明，將持續進行疫情調查，以釐清感染源。近期確診個案解隔離情形，5月11日至8月8日累計公布1萬4583名確診個案中，已有1萬3103人解除隔離，解隔離人數達確診人數89.9%。 陳時中表示，今天新增的3例本土個案都來自新北市，這是近期新增確診病例縣市別最少的一次，多數個案之間的關聯都能及時掌握，初步研判目前國內COVID-19疫情控制得還不錯。 今天新增5例境外移入個案，為2例男性、3例女性，年齡介於10多歲至60多歲，分別自法國（案15899）、美國（案15900、案15901）、印尼（案15904）及瑞士（案15906）入境，入境日介於6月28日至8月8日。 獨鍾莫德納疫苗不減反增 意願登記破400萬人 https://www.cna.com.tw/news/ahel/202108100335.aspx 指揮中心指揮官陳時中今天承諾保留第二劑莫德納疫苗，開放第一劑莫德納疫苗施打人數所剩不多，但截至今天下午5時，獨鍾莫德納疫苗民眾不減反增，意願登記破400萬人。 國內採購或獲贈莫德納（Moderna）的COVID-19（2019冠狀病毒疾病）疫苗總數共約855萬劑，以一人接種2劑計算，將以供427多萬人施打為目標，但據中央流行疫情指揮中心統計，截至9日莫德納疫苗已超過306萬人接種，初估國內僅剩不到100萬人可打莫德納疫苗。 此外，在全國意願登記完成總人數1339萬448人中，截至今天下午5時，僅勾選接種莫德納疫苗者已達400 萬1810人，比下午1時的399萬9260人更多，換句話說，陳時中即使在下午2時記者會承諾莫德納疫苗第一劑接種人數達目標，疫苗就不會再使用，但獨鍾莫德納疫苗者不減反增。 另截至今天下午5時的其餘疫苗登記狀況，與下午1時數據相比，僅勾選阿斯特捷利康（AZ）疫苗者為106萬3581人，占比從7.92%增至7.95%；非高端疫苗不打的民眾從18萬1974人增加為18萬2262人，但占比維持為1.36%。 若將只願意打高端疫苗人數及多重選擇COVID-19疫苗中有勾選高端疫苗者加總，意願登記高端疫苗總計105萬7577人，其中該系統7月27日重啟後才登記意願者為64萬1010人。 對抗Delta變異株 莫德納似優於輝瑞 https://www.cna.com.tw/news/firstnews/202108100080.aspx 根據刊載於醫學網站medRxiv的兩篇報告，美國輝瑞和德國BioNTech聯合研發的mRNA（傳訊核醣核酸）疫苗，在抵抗COVID-19的Delta變異株上，效力或許不及莫德納。路透社報導，這兩篇報告尚待同儕審查。medRxiv是收錄尚未發表且未經同儕審查的研究手稿的網路平台。 研究人員在一項針對梅約醫院醫療體系（Mayo Clinic Health System）5萬多名患者的研究中發現，莫德納疫苗的效力在2021年初有86%，到了7月，即疫情以Delta變異株為主流時，效力降至76%。同一期間，輝瑞/BNT疫苗的效力從76%降至42%。 隸屬麻州數據分析公司nference、主導梅約這份研究的桑達拉拉然（Venky Soundararajan）說，儘管兩支疫苗依舊可有效預防因新冠而住院，今年稍早注射輝瑞（Pfizer）/BNT或莫德納疫苗的民眾，可能很快就必須追加一劑莫德納加強劑。 而在另一份研究中，加拿大安大略省老人之家住民接種莫德納疫苗之後所產生的免疫反應，強過輝瑞/BNT疫苗，尤其在對抗讓人憂心的幾種變異株上。主導這項研究的多倫多「魯能費爾德-塔能鮑姆研究所」（Lunenfeld-Tanenbaum Research Institute）研究員金格拉斯（Anne-Claude Gingras）表示，年長者或許需要較高劑量、加強劑和其他預防措施。 路透社尋求輝瑞評論這兩份研究時，輝瑞發言人表示：「我們持續認為…完整接種之後的6到12個月內或許需要追加第3劑加強劑，以維持最高保護力。」 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v2 Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1 混打疫苗可行嗎？AZ混打輝瑞/BNT AZ混打莫德納等等 https://linshibi.com/?p=39613 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

With President Joe Biden cresting the first 100 days of his administration, experts are forecasting a strong economic rebound in the United States and Canada, but worries persist about the impacts of a third wave of the pandemic. BMO hosted the third in a series of panels on the road to recovery and how we're tracking recovery from a health, markets and macroeconomic perspective. Dan Barclay, CEO, BMO Capital Markets, moderated this discussion that included medical experts, Dr. John Whyte, Chief Medical Officer, WebMD, Dr. Allison McGeer, Senior Clinician-Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health and BMO's own Brian Belski, Chief Investment Strategist, BMO Capital Markets and Earl Davis, Head of Fixed Income & Money Markets, BMO Global Asset Management. For a transcript of this episode visit bmocm.com/covid19.

The published article, Science gave us excellent vaccines. Why bend the rules? in The Globe and Mail addresses the challenges in altering the recommended two-dose schedule for the two Canadian approved mRNA vaccines, Pfizer-BioNTech and Moderna. In this episode of Emerging Topics, we speak to one of the authors, Dr. Alan Bernstein to tell us more about these challenges and what considerations should be taken on whether or not to delay the second-dose. Dr. Alan Bernstein is the President and CEO of the Canadian Institute for Advanced Research (CIFAR), which is a Canadian-based, global research organization. He is one of Canada's foremost scientists with several decades of work in research leadership. A graduate from the University of Toronto, he received the James Loudon Gold Medal in Physics, and completed his PhD research with James Till. After roles at the Ontario Cancer Institute and Lunenfeld Tanenbaum Research Institute, Dr. Bernstein was asked to become the founding President of the Canadian Institutes of Health Research, where he led the transformation of health research in Canada, creating Canada’s first health research institutes. He was also an early champion of women in science and young scientists. In 2010, Dr. Bernstein became Executive Director of the Global HIV Vaccine Enterprise in New York, where he led an international alliance of organizations funding HIV vaccine research. Author of over 225 scientific publications, Dr. Bernstein has made landmark contributions to the study of stem cells, blood cell formation (hematopoiesis) and cancer. He chairs or is a member of advisory and review boards in Canada, the U.S., U.K., Italy and Australia. He serves as co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer Canada AND is a member of both the Sabin-Aspen Vaccine Science and Policy Group, and the Scientific Advisory Committee of the Bill and Melinda Gates Foundation. In May 2020, Dr. Bernstein was appointed to Canada’s COVID-19 Vaccine Task Force. His contributions to science and science policy have been recognized with numerous awards and honorary degrees, including Officer of the Order of Canada, Order of Ontario, the McLaughlin Medal from the Royal Society of Canada, the Award of Excellence from the Genetics Society of Canada, the Gairdner Foundation Wightman Award, induction into the Canadian Medical Hall of Fame, and the 2017 Henry Friesen International Prize in Health Research.

Episode 51 BEaTS Research Radio - Interview with Dr. James Woodgett. Dr. Mo Al-Khalaf from the University of Ottawa Heart Institute talks to Dr. James Woodgett, Director of Research at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System. A conversation about James Woodgett’s view on the Science and Policy path and the importance of communicating Science to our communities. Learn more about the Lunenfeld-Tanenbaum Research Institute: www.lunenfeld.ca

As Canada and the United States begin the roll-out of a game-changing vaccine against COVID-19, BMO hosted a panel with in-house and external experts to discuss the implications from a health, markets and macroeconomic perspective, including where we are now, when a new normal might begin and what it will look like. The panel was moderated by Chief Investment Strategist Brian Belski, and featured medical commentary from Dr. John Whyte, Chief Medical Officer, WebMD, and Dr. Allison McGeer, Senior Clinician-Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health. BMO experts, Deputy Chief Economist Michael Gregory and Margaret Kerins, Head of FICC Macro Strategy, discussed the economic and fixed income and equity market outlook for Canada and the United States. To access our full disclosures, please visit: https://researchglobal0.bmocapitalmarkets.com/public-disclosure/ 

BMO hosts a panel discussion featuring Dr. John Whyte, Chief Medical Officer, WebMD and Dr. Allison McGeer, Senior Clinician-Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Brian Belski, Michael Gregory and Margaret Kerins, as regions across Canada and the United States look to deploy vaccines against COVID-19. Our experts will discuss how we're managing through the pandemic from a health, markets and macroeconomic perspective and provide commentary on the outlook.

ST: A Palliative Approach to Decision Aids to Help Improve Patients’ Medical Choices Pete Wegier in this interview with Ross Upshur discusses complexities of the end of life care and how coordination in this care setting could be optimized by the use of new communication technologies. Interestingly, his journey from computer science to cognitive psychology, to medical decision making and later to the space of palliative care has equipped Pete with tools that could help untangle some of the problems in this most complex area in health care.   In the podcast, Pete also discusses how his research interests concern medical decision making, focusing on the effective communication of information to both patients and physicians to improve understanding in medical choices. Specifically, he focuses on the use of simulated experience as a decision aid for medical decision making; the effective communication of quantitative information in healthcare, specifically through data visualization; and how healthcare teams collaborate in distributed settings via online communication platforms. Dr. Pete Wegier is a medical decision scientist at the Temmy Latner Centre for Palliative Care and the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, and an assistant professor in the Department of Family and Community Medicine at the University of Toronto. A cognitive psychologist by training, Dr. Wegier’s work focuses on techniques for the early identification of patients that may benefit from a palliative approach to their care, as well as the design and creation of patient education materials and decision aids to help improve patients’ medical choices. Pete holds a PhD in psychological science and a BSc and MSc in computer science. He has undertaken postdoctoral training at the University of Missouri. Here are some of Pete Wegier’s publications indexed in ResearchGate, so far.

Michelle Nelson in an interview with Ross Upshur discusses the importance of intra- and inter-sectoral collaboration in healthcare and explains how the voluntary sector could be engaged to support improved patient and family experiences and the outcomes. In a recent interview with Ross Upshur, Michelle Nelson, a Research Scientist at Research Collaboratory, Lunenfeld-Tanenbaum Research Institute, explained about her research, the importance of intra- and inter-sectoral collaboration in health care, engagement of the voluntary sector to support improved patient and family experience and the patient outcomes. Michelle has been actively pursuing development of a complexity and stroke rehabilitation research network. Her tireless efforts recently led to holding a meeting attended by 43 researchers, policy-makers and clinicians. The meeting initially generated 120 potential research questions, from which 16 high-priority questions were identified focusing on complexity characteristics including multimorbidity, social determinants, patient characteristics, social support and system factors (1). In this recent work, Michelle and her colleagues put the emphasis on expanding the kind of research that focuses beyond the single disease approach, and try to help understand complex patients and their care needs. This approach, as they put it, will not only help stakeholders to better understand and provide integrated stroke rehab care for complex patients but it will also help improve patient outcomes that would ultimately lead to a more developed and advanced health care system. Dr. Nelson is a Research Scientist within the Lunenfeld-Tanenbaum Research Institute in Toronto, Canada. She also holds academic appointments in the Institute of Health Policy, Management and Evaluation at the University of Toronto, and Ryerson University in the School of Nursing. Her research is concentrated on patient complexity (the intersection of health conditions and social determinants); specifically examining issues related to the management of patient complexity, health profession education/collaborative practice, and community reintegration. From 2005 – 2009 she was the Research Director for a Health Canada funded Interprofessional Education program within geriatrics. She was the Principal Investigator for two Canadian Institutes of Health Research grants focused on patient complexity and rehabilitation. As a result, she convened national rehabilitation experts and stakeholders to develop a multidisciplinary, multisectoral research agenda specific to patient complexity in stroke rehabilitation. In 2014, Dr. Nelson received a $600,000 grant to examine how the voluntary sector could be engaged to support improved patient/family experiences and outcomes. So far, she has published over 40 articles and reports specific to issues of complexity, clinical practice, rehabilitation, collaboration, and the role of the voluntary sector in meeting patient needs. She is a sought after committee member for rehabilitation strategic planning, clinical guideline development and knowledge translation. In 2017, she was a visiting professor at the Queensland University of Technology, engaging colleagues in collaborative work related to patient complexity. Michelle was elected to the Board of Governors for the World Stroke Organization and nominated to the Executive in August 2018. Some of Michelle’s papers indexed in Google Scholar by September 2018. Reference: Nelson ML, McKellar KA, Munce S, Kelloway L, Hans PK, Fortin M, et al. Addressing the Evidence Gap in Stroke Rehabilitation for Complex Patients: A Preliminary Research Agenda. Arch Phys Med Rehabil. 2018;99(6):1232-41.

Dr. Collingridge was recruited from Bristol in the U.K. to be the Senior Investigator at Lunenfeld-Tanenbaum Research Institute in Toronto. He is also the chair of the Department of Physiology at the University of Toronto. Dr. Collingridge studies brain mechanisms that control the strength of brain cell connections, and how this fundamental property (known as synaptic plasticity) affects brain function. The work is critical for understanding the cellular basis of learning and memory. Dr. Collingridge aims to find pharmacogenetic methods (drugs) to restore behavioural and cognitive function and to prevent neurodegenerative processes that afflict people with Alzheimer’s and Parkinson’s Disease, and mental illness. From why smells reminds us of our past to research on medication that can reverse the affects of depression to pruning our synapses and the best way to keep our brain young. Enjoy!   Scent Music and Memory (6:00) 10% of our Brain (8:30) Cant Remember Everything (9:00) Plasticity (11:20) Metaplasticity (13:10) Improving memory (14:30) Weaken fear response (17:40) Immune System & Nervous System (26:30) Nervous system variability (27:00) Stress on the brain (33:40) Medication for Alzheimer’s (36:00) Ketamine and depression (37:30) Peak plasticity in life (43:20) Raise pain threshold (44:30) Inflammation and memory (50:00) Marijuana vs. Alcohol (56:20) Keeping your brain young (1:01:20) Send me an Email! ben@heroicminds.live   Work Cited: Park, Pojeong, et al. "NMDA receptor-dependent long-term potentiation comprises a family of temporally overlapping forms of synaptic plasticity that are induced by different patterns of stimulation." Phil. Trans. R. Soc. B 369.1633 (2014): 20130131. Nisticò, Robert, et al. "Synaptoimmunology-roles in health and disease." Molecular brain 10.1 (2017): 26. Bliss, T. V. P., G. L. Collingridge, and R. G. M. Morris. "Synaptic plasticity in health and disease: introduction and overview." (2014): 20130129. Bortolotto, Zuner A., et al. "An analysis of the stimulus requirements for setting the molecular switch reveals a lower threshold for metaplasticity than synaptic plasticity." Neuropharmacology 55.4 (2008): 454-458.

Joining me on this episode is Bibaswan Ghoshal. He is a Senior Bioinformatician at the Lunenfeld Tanenbaum Research Institute of Mount Sinai Health System in Toronto. He has his Master’s of Science in Medicine and finishing his PhD in Bioinformatics, Animal Microbiome and Agriculture from the University of Alberta. On this episode we discuss…The number of microbes in inside us and how they help usFactors/technology that impacted the start of this new fieldDifferences between studying the human microbiome and genomeTechniques/technologies used to study the microbiomeHuman Microbiome ProjectHealthy microbiomesFactors that affect microbiomesVariations between people’s microbiomesMicrobiome researchRole of a bioinformatics analyst in microbiome research Learn more about the microbiome through the University of Utah’s free interactive modules. You can follow Bibaswan on Twitter @bibaswanghoshal and read his blog at worldofbiba.wordpress.com. Check out the books Bibaswan recommends during the episode: Brain Maker by Dr. David Perlmutter and I Contain Multitudes by Dr. Ed Yong. Stay tuned for the next new episode of DNA Today on April 20th, 2018 where I will be interviewing Rafi Mendelsohn about a free DNA test for adoptees and biological families to be reunited. It's offered through April through MyHeritage's DNA Quest. New episodes are released on the first and third Fridays of the month. See what else I am up to on Twitter, Instagram, Facebook and iTunes. Questions/inquiries can be sent to info@DNApodcast.com

Dr. Bernard Zinman is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute in Toronto. He has been involved with many advances in diabetes treatment and care and is a world-leader in the diabetes field.

Sarina Isenberg, interviewed by Ross Upshur, discusses palliative care from the lens of a scientist and health researcher committed to making a difference for those who receive such care in the course of their disease. Sarina’s first experience with palliative care was at a relatively young age when two loved ones were in palliative care in the course of their terminal illnesses. Later, her studies in health-related subjects landed Sarina in palliative care study and research, which is a subject area with great challenges in any health system in the world in terms of complexity, cost and degree of needed care. As mentioned in the podcast, palliative care is no longer limited to end-of-life care. The shifting face of palliative care, in light of the aging population in Canada, is a great opportunity for Sarina and others to research palliative care with the intent of improving access to, and the quality of palliative care. Sarina Isenberg is a Scientist at the Temmy Latner Centre for Palliative Care and the Lunenfeld-Tanenbaum Research Institute (both at Sinai Health System), as well as an Assistant Professor in the Department of Family and Community Medicine – Division of Palliative Care at the University of Toronto. Her research has leveraged  varied health services approaches—both quantitative and qualitative—to assess access to and quality of palliative care,(1, 2) evaluate the cost effectiveness of palliative care inpatient services,(3, 4) and test interventions for improving advance care planning discussions.(5-7) Sarina’s ongoing work also relates to evaluating the cost effectiveness of home-based palliative care, assessing the patient and caregiver experience of receiving palliative care, transitioning across palliative care settings, and designing and implementing quality improvement initiatives in palliative care. Sarina’s central research goal is to apply a public health approach to palliative care research that is translatable to decision-makers, practitioners, patients, and their companions. Sarina has worked with knowledge users translating research into practice and policy through collaborations with Ontario Palliative Care Network, Veterans Affairs Canada,(8) the American Society of Clinical Oncology,(9) and the Agency for Health Research and Quality. (10) Sarina received her PhD in Social and Behavioral Sciences at the Johns Hopkins Bloomberg School of Public Health. She has previously worked as a management consultant on Deloitte’s National Health Services Team (Canada). Prior to consulting, Sarina received her MA in English Literature from Queen’s University and her BA in English Literature from McGill University. Find out how she puts those humanities degrees to work in her role as a scientist in this podcast. Link to some of Sarina’s articles on PubMed, so far.  References in this article: 1. Aslakson R, Dy SM, Wilson RF, et al. Patient and caregiver-reported assessment tools for palliative care: summary of the 2017 AHRQ Technical Brief. J Pain Symptom Manage. 2017 Aug 14. PubMed PMID: 28818633. Epub 2017/08/19. eng. 2. Dy SM, Al Hamayel NA, Hannum SM, et al. A survey to evaluate facilitators and barriers to quality measurement and improvement: Adapting tools for implementation research in palliative care programs. J Pain Symptom Manage. 2017 Aug 08. PubMed PMID: 28801007. Epub 2017/08/13. eng. 3. Isenberg SR, Lu C, McQuade J, et al. Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions. Journal of Oncology Practice. 2017;epub ahead of print. 4. Isenberg SR, Lu C, McQuade J, et al. Economic Evaluation of a Hospital-Based Palliative Care Program. Journal of Oncology Practice. 2017;epub ahead of print. 5. Aslakson RA, Isenberg SR, Crossnohere NL, et al. Utilizing Advance Care Planning Videos to Empower Perioperative Patients and Families: The Protocol...

Over the past decade, academics and media outlets alike have been telling us that stem cells are going to revolutionize regenerative medicine. But what does this really mean? What are stem cells, how do they work and why have they been generating so much public interest? On this episode, Richie sits down with Dr. Andras Nagy, world-renowned Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, to discuss his breakthroughs in stem cell research and the ethical challenges facing the field. We also hear from Anton and James, as they break down the history of stem cell research and where we stand today. They also speak on how stem cell hype can be harmful to patients.

Over the past decade, academics and media outlets alike have been telling us that stem cells are going to revolutionize regenerative medicine. But what does this really mean? What are stem cells, how do they work and why have they been generating so much public interest? On this episode, Richie sits down with Dr. Andras Nagy, world-renowned Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, to discuss his breakthroughs in stem cell research and the ethical challenges facing the field. We also hear from Anton and James, as they break down the history of stem cell research and where we stand today. They also speak on how stem cell hype can be harmful to patients.

Carolyn Steele Gray, in interview with Ross Upshur, discusses how her academic journey shaped her perspectives in understanding patient needs, health policy, organization and provider level issues and how to use that understanding to deliver a better care. The latter, she adds, necessitates a realistic approach of how to harness e-health technologies to deliver care, especially to patients with complex care needs. Carolyn discusses how technology in health is not the silver bullet to healthcare questions and its implementation is embedded within complex social layers, affected by people’s feelings about it; policy issues surrounding it; and how organizations treat it. Carolyn describes the value of adopting a user-centred design evaluation approach used to develop the ePRO tool; describing how it evolved from a tool intended to collect patient-reported outcome measures to one that enables patient-centred goal-oriented care within primary care settings. The talk addresses some of the current challenges in the use of e-health technologies in the healthcare system highlighting tensions faced by researchers and adopters. Carolyn is a Scientist at the Bridgepoint Collaboratory for Research and Innovation at the Lunenfeld-Tanenbaum Research Institute, Assistant Professor at the Institute of Health Policy, Management and Evaluation (University of Toronto), as well as an investigator with the Health System Performance Research Network (University of Toronto). Carolyn’s research focuses on the role of health information technology in supporting person-centred care delivery for individuals with complex care needs. Her research explores how technology can be leveraged to enable implementation and sustainability of innovative models of care as a means to support health system transformation. Carolyn received her PhD in Health Policy from the University of Toronto (2013), and a Master’s in Public Policy and Administration from Ryerson University (2008). Prior to her current role as a Scientist, she was a postdoctoral fellow working at the University of Toronto and the Health System Performance Research Network. For a full bio, please follow this link. Carolyn has published work in the areas of eHealth and mHealth, organizational change, health policy and patient-centred care delivery. Some of Carolyn’s papers indexed in PubMed so far.

Diabetes Canada funds millions of dollars in research every year towards improved diabetes treatments and, one day, a cure. In today’s episode, Toronto’s Dr. Bruce A. Perkins of the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital discusses what it’s like to be a diabetes researcher and endocrinologist while living with type 1 diabetes. He also explains his work in the areas of diabetic neuropathy (nerve damage), diabetic kidney disease and strategies to help improve blood sugar control, which includes the working on the artificial pancreas.

Keeping with the theme of Student Engagement, we’re ending the month with the woman who has figuratively (and nearly literally) done it all, Dr. Darlene Homonko! She’s Director of the Office of Technology Transfer and Industrial Liaison at the Lunenfeld-Tanenbaum Research Institute and, she took the time to share her incredibly winding journey with us. Dr. Homonko tells us why it’s okay to switch fields once, twice, or maybe even five times, why failure is a boon to personal growth, and offers her advice to students who aren’t sure what the heck they want to do after grad school. Finally, Melissa dishes the inside scoop on the Graduate Professional Skills (GPS) program by catching up with Liam O’Leary- Graduate Programming Coordinator for the School of Graduate Studies at the University of Toronto— who discusses the nitty gritty of GPS, and gives his top picks from the program. If you’re in need of a pep-talk, this is just the episode. Until next time, keep it raw!

Keeping with the theme of Student Engagement, we’re ending the month with the woman who has figuratively (and nearly literally) done it all, Dr. Darlene Homonko! She’s Director of the Office of Technology Transfer and Industrial Liaison at the Lunenfeld-Tanenbaum Research Institute and, she took the time to share her incredibly winding journey with us. Dr. Homonko tells us why it’s okay to switch fields once, twice, or maybe even five times, why failure is a boon to personal growth, and offers her advice to students who aren’t sure what the heck they want to do after grad school. Finally, Melissa dishes the inside scoop on the Graduate Professional Skills (GPS) program by catching up with Liam O’Leary- Graduate Programming Coordinator for the School of Graduate Studies at the University of Toronto— who discusses the nitty gritty of GPS, and gives his top picks from the program. If you’re in need of a pep-talk, this is just the episode. Until next time, keep it raw!